← Leaderboards
Michael Keith Wendt
Purdue University
$4,884,793
Attributed
$8,545,412
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2013–25$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,545,412 · 8
By mechanism
R01$7,276,809 · 4
R00$705,847 · 1
R21$280,414 · 1
P30$159,033 · 1
K99$123,309 · 1
Top collaborators
- Stephen D Hursting10 shared
- Dorothy Teegarden10 shared
- Luis Solorio2 shared
- Richard M. Van Rijn2 shared
Most similar at Purdue University
Same institution · by research overlap
- Stephen D Hursting$11,090,787
- Dorothy Teegarden$3,870,838
Others in their field
Top investigators on “Neoplastic Cell”
- David Heimbrook · Leidos Biomedical Research, Inc.$139,710,838
- Gregory H Reaman · National Childhood Cancer Foundation$31,993,642
- Bruce W Stillman · Cold Spring Harbor Laboratory$25,455,900
- Ralph Parchment · Leidos Biomedical Research, Inc.$25,266,647
- Andrea Califano · Columbia University Health Sciences$22,374,316
- Wendell A Lim · University Of California, San Francisco$22,334,734
Research focus
Neoplastic CellNeoplasm MetastasisCellsMalignant Breast NeoplasmMalignant NeoplasmsGeneticSitePrimary NeoplasmPreventReporterTargeted TreatmentEnvironmentBreast Cancer CellRecurrenceMolecularExtracellular MatrixMediatingUp-RegulationBreast Cancer MetastasisOverexpressionTumorMouse ModelPositioning AttributeCessation Of Life
Grant awards (25)
Impact of hypoxia on lipid metabolism in obesity-driven breast cancer progression$641,634
R01 · FY2025 · CA
Engineering the Premetastatic Niche$521,240
R01 · FY2025 · CA
Experimental Therapeutics$125,145
P30 · FY2025 · CA · contact PI
Impact of hypoxia on lipid metabolism in obesity-driven breast cancer progression$609,551
R01 · FY2024 · CA
Engineering the Premetastatic Niche$521,240
R01 · FY2024 · CA
Experimental Therapeutics$33,888
P30 · FY2024 · CA · contact PI
Impact of hypoxia on lipid metabolism in obesity-driven breast cancer progression$655,384
R01 · FY2023 · CA
Obesity, Metabolism and Breast Cancer Metastasis$449,604
R01 · FY2023 · CA
Obesity, Metabolism and Breast Cancer Metastasis$449,604
R01 · FY2022 · CA
Obesity, Metabolism and Breast Cancer Metastasis$186,309
R01 · FY2022 · CA
Obesity, Metabolism and Breast Cancer Metastasis$458,781
R01 · FY2021 · CA
Overcoming metastatic resistance to ErbB-targeted therapies$349,001
R01 · FY2021 · CA · contact PI
Obesity, Metabolism and Breast Cancer Metastasis$116,581
R01 · FY2021 · CA
Obesity, Metabolism and Breast Cancer Metastasis$458,780
R01 · FY2020 · CA
Overcoming metastatic resistance to ErbB-targeted therapies$349,110
R01 · FY2020 · CA · contact PI
Obesity, Metabolism and Breast Cancer Metastasis$472,530
R01 · FY2019 · CA
Overcoming metastatic resistance to ErbB-targeted therapies$338,739
R01 · FY2019 · CA · contact PI
The influence of alcohol on the metastatic dormancy of breast cancer$140,207
R21 · FY2019 · AA · contact PI
Overcoming metastatic resistance to ErbB-targeted therapies$349,322
R01 · FY2018 · CA · contact PI
The influence of alcohol on the metastatic dormancy of breast cancer$140,207
R21 · FY2018 · AA · contact PI
Overcoming metastatic resistance to ErbB-targeted therapies$349,399
R01 · FY2017 · CA · contact PI
Targeting FGFR to prevent the outgrowth of metastatic breast cancer$238,579
R00 · FY2016 · CA · contact PI
Targeting FGFR to prevent the outgrowth of metastatic breast cancer$243,591
R00 · FY2015 · CA · contact PI
Targeting FGFR to prevent the outgrowth of metastatic breast cancer$223,677
R00 · FY2014 · CA · contact PI
Targeting FGFR to prevent the outgrowth of metastatic breast cancer$123,309
K99 · FY2013 · CA · contact PI